As NASH Space Heats Up, Tobira Strengthens Position With Regado Reverse-Merger

New combined company, with $60 million in cash, is hoping to move quickly to fill the unmet medical need of non-alcoholic steatohepatitis. Tobira expects primary endpoint data from a Phase IIb study of cenicriviroc by the second quarter of 2016.